Corgi | $108,000,000 | (Jan 9, 2026)
Corsera Health | $80,000,000 | (Jan 9, 2026)
Oasys | $4,600,000 | (Jan 9, 2026)
Certified by Founder
Lodge
En Carta Diagnostics
start up
France
- Paris
- 23/05/2024
- Pre-Seed
- $1,623,697
Diagnostics for Better care, Everywhere.
En Carta Diagnostics is a synthetic-biology biotech company leveraging patented technologies to decentralise highly reliable molecular diagnostic solutions.
- Industry Biotechnology Research
- Website https://www.encarta.bio/
- LinkedIn https://www.linkedin.com/company/en-carta-diagnostics/
Related People
Guillaume HorréardCo Founder
France -
Paris, Île-de-France
As the Co-founder and CEO of En Carta Diagnostics, I am dedicated to simplifying the world of diagnostics, making them as accessible as antigenic tests.
Our vision is to revolutionize healthcare by bringing diagnostics to every corner of the globe for better patient care.
Feel free to connect with me to discuss opportunities, collaboration, or to explore how we can advance healthcare and product development together.
Vizgen | $48,000,000 | (Jan 9, 2026)
Poplar Therapeutics | $50,000,000 | (Jan 9, 2026)
Carna Health | $8,000,000 | (Jan 9, 2026)
Valinor(US) | $54,000,000 | (Jan 9, 2026)
Alveus Therapeutics Inc | $160,000,000 | (Jan 9, 2026)
AgileRL | $7,500,000 | (Jan 9, 2026)
Soley Therapeutics | $200,000,000 | (Jan 9, 2026)
EpiBiologics | $107,000,000 | (Jan 9, 2026)
SpangleAI | $15,000,000 | (Jan 9, 2026)
Presto Phoenix, Inc. | $10,000,000 | (Jan 9, 2026)